Mixed litigation news for Avadel

29 August 2024

Ireland-headquartered Avadel Pharmaceuticals (Nasdaq: AVDL)has updated on litigation with USA-based Jazz Pharmaceuticals (Nasdaq: JAZZ).

Avadel revealed in a Securities and Exchange Commission (SEC) filing that, on August 27, 2024, the US District Court for the District of Delaware issued a decision denying a request by Jazz Pharmaceuticals for a permanent injunction to enjoin its Avadel CNS Pharmaceuticals subsidiary from making, using, selling, offering to sell and/or importing Lumryz for its US Food and Drug Administration (FDA)-approved indication for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy.

Avadel said it is pleased with the Court’s decision allowing the commercial launch of Lumryz in narcolepsy to proceed without interruption.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK